a Patients with stop date and stop reason recorded or with at least 6 months of IPT on 15 June 2013. b Includes only patients with an IPT outcome (n ¼ 470 for 1-15 years and n ¼ 1280 for >15 years).
We assessed isoniazid preventive therapy (IPT) completion and predictors among HIV-infected children and adults in two HIV clinics in Kinshasa, Democratic Republic of Congo. Between 1 September 2012 and 15 June 2013, 546 children (1-15 years) and 1532 adults (>15 years) were initiated on IPT; 86.6% (408/470) of the children and 88.2% (1129/1280) of the adults with an IPT outcome completed their therapy. Patients on antiretroviral therapy at IPT initiation were more likely to complete IPT.
Isoniazid preventive therapy (IPT) has been recommended for people living with HIV (PLWH) since 1998 [1] . Yet, at the end of 2013, only 21% of countries globally and 14 of 41 high-burden tuberculosis (TB)/HIV countries reported provision of IPT [2] . The lack of IPT implementation has been driven among other by concerns regarding inadequate patient adherence potentially leading to isoniazid monoresistance [3] . A recent review of data from trials of IPT found that adherence rates for IPT varied widely, from 34 to 98% [4] [5] [6] [7] [8] . To the best of our knowledge, there has been no report on IPT compliance among PLWH receiving IPT as part of comprehensive HIV care in sub-Saharan Africa.
The aim of this study was to assess IPT completion and factors associated with IPT completion among HIVinfected children and adults receiving it as part of their routine HIV care in two clinics (Kalembe Lembe and Bomoi) in Kinshasa, Democratic Republic of Congo (DRC). Clinical procedures in the two clinics have been reported elsewhere [9, 10] .
Starting in April 2012, patients receiving care in those clinics were screened at each visit for TB symptoms. Active TB was ruled out in adults if they did not have any of current cough, night sweats, fever, and weight loss, and in children if they did not have any of poor weight gain, fever, current cough, or contact history with a TB case [11] . In August 2012, the two clinics started providing IPT according to WHO guidelines to all HIV-infected patients 1 year or older in whom active TB was ruled out for a minimum of 6 months, irrespective of previous TB or antiretroviral therapy (ART) history.
The main outcome in this analysis was IPT completion. All patients recorded to have stopped taking IPTwith the reason for stopping recorded as 'treatment completion' were classified as having completed their treatment. If they had been on IPT for at least 6 months, but were not recorded as 'treatment completion', they were classified as not completed. Patients in whom IPTwas stopped before 6 months were classified as not completed, regardless of the reason for stopping.
Bivariate and multivariate logistic regression models were used to estimate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between baseline predictors and IPT completion. All analyses were done separately for children (15 years or younger at IPT initiation) and adults (over 15 years at IPT initiation). All analyses were performed using SAS 9.3 (Cary, North Carolina, USA).
Between 1 September 2012 and 15 June 2013, 3053 PLWH receiving care in the two clinics had at least one clinic visit. Of those, 2366 were not symptomatic, and 2078 (87.8%) were initiated on IPT. This included 546 children (26.3%) and 1532 adults (73.7%) ( Fig. 1 , supplemental material, http://links.lww.com/QAD/ A743).
Among the 546 children initiated on IPT, the median age was 8.0 years [interquartile range (IQR) 4.6, 11.2]. They had been in care for a median of 39.3 months (IQR 4.6, 11.2), and over 90% (n ¼ 494) were on ART (Table 1) . Overall, 470 (86.1%) had an IPT outcome (termination date and reason recorded: n ¼ 431) or had been on treatment for more than 6 months (n ¼ 39). Of those, 408 (86.8%) completed their IPT. Children on ART at IPT initiation were more likely to complete IPT (adjusted OR 1.70, 95% CI 0.75, 3.85) ( (Table 1) . Overall, 1280 (83.6%) had an IPT outcome (termination date and reason recorded: n ¼ 1188) or had been on treatment for more than 6 months (n ¼ 92). Of those 1280, 1129 (88.2%) completed their IPT. Participants on ART at IPT initiation were more likely to complete IPT than those who were not (89.2 vs. 83.3%; adjusted OR 1.54, 95% CI 1.02, 2.32). Higher age at IPT initiation was also associated with IPT completion (adjusted OR 1.02, 95% CI 1.00, 1.04) for each year increase in age ( Table 2 , supplemental material, http://links.lww.com/QAD/ A743). This is the first report on IPT completion among PLWH who received IPT during routine care in sub-Saharan Africa. Our results showed that among both children and adults, the proportion of patients who completed 6 months of IPT was high (>85%). This is a conservative estimate given that every participant with over 6 months of IPTwithout a stop date or reason recorded was treated as a failure to complete.
Our observed high proportion of PLWH who completed 6 months of IPT is the same as that observed in a TB vaccine trial in Tanzania (87%) [12] and in public primary HIV clinics in Brazil (85%) [13] . A small study of IPT among pregnant women in Lesotho reported a lower proportion of IPT completion (64.5%) [14] , probably due the high postpartum dropout that has been well documented among HIV-infected pregnant women [15] .
Adherence to TB-preventive therapy among HIVinfected children has also been shown to be very good: 75.8% in a prospective study of ofloxacin, ethambutol, and high-dose isoniazid in South Africa [16] or 78.6% in a randomized trial comparing daily to thrice weekly dosing of isoniazid in South Africa [17] .
The present study has some limitations. This is a retrospective analysis and detailed information was not always available. For example, the types and severities of reported toxicities were not recorded. Over 8% of children and 7% of adults initiated on IPT for more than 6 months lacked information in the database on whether they were still taking the treatment. Part of this might be explained by the gap between the visit to the clinic and data entry, but we have conservatively classified those patients as noncompleters.
In conclusion, in our cohort of HIV-infected children and adults receiving IPT as part of their routine HIV care and treatment, the proportion of patients completing the 6-month regimen was relatively high, and being on ART at IPT initiation was the strongest predictor of completion. thank the National TB and HIV programs of the Ministry of Health of the DRC, as well as staff at Bomoi Healthcare Center and Kalembe Lembe Pediatric Hospital, for their substantial contributions to the success of this study.
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Comparing the results of HIV trials using different endpoints and scale is a difficult task. The two main primary endpoints are the proportion of patients with HIV-1 RNA less than 50 copies/ml at week 48 and the time to virologic failure. In the A5202 study, the use of the risk difference scale instead of the risk ratio scale would have led to equivalence in the comparisons between efavirenz and atazanavir/ ritonavir. We discuss these results and their impact on the design of the A5257, as well as alternative approaches.
Noninferiority randomized clinical trial has emerged as the new standard design to investigate the efficacy of HIV drugs. Such trials aim to demonstrate that an experimental treatment is not unacceptably worse than the standard regimen. Clinicians often compare results between trials, even if they differ in design and analysis. The definition of the primary endpoint is, in many cases, the most apparent difference between the studies. Two primary endpoints are widely used in HIV trials: the proportion of participants with HIV-1 RNA less than 50 copies/ml at week 48 (primary endpoint 1) and the time from randomization to virologic failure (primary endpoint 2) often used by the AIDS Clinical Trials Group (ACTG).
The choice of effect measure (scale) has been widely discussed for epidemiological data but less for clinical data [1] [2] [3] . Three main measures are used for binary data: risk difference, risk ratio and odds ratio (OR). The choice of the primary endpoint drives partly the choice of both the scale and the statistical methods for the analysis. Trials with primary endpoint 1 use a risk difference scale, whereas those with primary endpoint 2 use a risk ratio scale with estimates provided by a proportional hazards model (hazard ratio; HR). In the latter endpoint, estimates of the survival function by Kaplan-Meier curves offer a complementary analysis providing the cumulative proportion of failure at any time in the study.
In the Kaplan-Meier method, the censoring mechanism is assumed to be noninformative. Bounds for the survival function have been given by Peterson and the basic idea behind them is straightforward [4] : for example, suppose that by week 96, 5% of individuals experienced virologic failure and 15% have been censored without experiencing the virologic failure, the failure rate at week 96 is bounded between 5% and 20%. Although apparent purely virologic, the primary endpoint 1 is, in practice, a composite endpoint: indeed, patients who discontinued or modified their randomized regimen before week 48, as well as patients with missing HIV RNA data in the analysis window, are usually regarded as failures. Consequently, primary endpoint 1 is also a cumulative proportion of failure. To my knowledge, OR is less commonly used in the analysis of HIV randomized trials.
The ACTG 5202 study compared four regimens, atazanavir/ritonavir versus efavirenz (EFV) each with a combination of abacavir/lamivudine (ABC/3TC) and tenofovir/emtricitabine [5] . A primary endpoint 2 was used with virologic failure defined as a confirmed HIV RNA level of at least 1000 copies/ml at or after 16 weeks and before 24 weeks or at least 200 copies/ml at or after 24 weeks [6] . Regimens were prespecified to be equivalent if the two-sided 95% confidence interval (CI) for the HR from a Cox proportional hazards model was between 0.71 and 1.40. Interestingly, margins were first defined for risk difference scale and then translated for HR. Specifically, the A5202 team felt that a difference of 10% in the probability of virologic failure by week 96 was acceptable for equivalence. Assuming a probability of virologic failure of 31.89% (hazard of 0.004) and 41.58% (hazard of 0.0056) by week 96 in the two regimens being compared leads to a HR for virologic failure of 0.71 (0.004/0.0056) and 1.40 (0.0056/0.004). Hazards were computed in assuming an exponential distribution for the time to virologic failure.
In the A5202 study, the difference in Kaplan-Meier estimates at week 96 provided an estimate of the risk difference between two treatment arms with a AE10% margin for equivalence. Margins for an analysis based on OR are easily computed. With probability of virologic failure of 31.89% at week 96 (probability of success ¼ 68.11%) and a 10% difference, the upper bound of the OR margin is (68.11/31.89)/(68.11 À 10)/ (31.89 þ 10) ¼ 1.54 and the lower bound is (1/ 1.54) ¼ 0.65.
The top of the Table 1 summarizes the results of the A5202 study as presented in the final publication [6] . At the end of the follow-up, the HR (EFV being the reference) for time to virologic failure was 1.13 (95% CI, 0.82 to 1.56) in the ABC/3TC group and 1.01 (95% CI, 0.70 to 1.46) in the tenofovir/emtricitabine group. Neither CI reached the prespecified equivalence boundaries such that the results were inconclusive. However, the two 95% CI for the differences in Kaplan-Meier estimates at week 96 are within AE10%, indicating that, on the risk difference scale, equivalence was met. Thus, when estimated with the Kaplan-Meier method, the difference in the cumulative proportion of virologic failure is within 10% at week 96 as laid down in the protocol.
The bottom of the Table 1 displays an alternative analysis based on bounds of the Kaplan-Meier estimates at week 96 and on incidence rate ratio with full follow-up. The number of participants censored at week 96 can be obtained from the published results [6] . For example, there were 63 virologic failures by week 96 from the 465 patients randomized in the EFV/ABC/3TC group with 331 patients still at risk. It follows that 71 (465 -63 -331) participants were censored before week 96. Therefore, the upper bound of the failure rate is (63 þ 71)/465 (28.8%) and the lower bound is 63/465 (13.5%). Analyses based on the lower bound provide again discordant conclusion: both 95% CI for risk difference estimates met equivalence boundaries whereas neither of the two 95% CI for OR estimates met equivalence boundaries. Incidence rate ratio estimates are similar to HR estimates leading to similar conclusions.
Limitations of HRs have been previously discussed, in particular assuming constant HRs and in the presence of competing risks [7, 8] . In addition to the risk difference, a recent study recommends the use of differences of restricted mean survival times [9, 10] . Such an alternative seems very promising in randomized noninferiority trials although margins may not be intuitive for clinicians. Other approaches have been introduced based on the use of flexible generalized gamma-distribution when the assumption of proportionality for the hazards is suspected to be not valid [11] [12] [13] . In these analyses, the difference between the trial's arm is expressed in differences of percentiles providing an attractive alternative [11] .
We believe that the discordant findings from the A5202 study affected the design of a recent ACTG study (A5257) because the risk difference assessed by the difference between the two Kaplan-Meier estimates shows much less variability than the HR estimate. Results of the A5202 contributed to promote Kaplan-Meier estimates as primary efficacy analyses. Indeed, in the large A5257 study comparing efficacy and safety of three randomized groups, the primary endpoint is the same as in the A5202 study [14] . However, the primary efficacy analysis of the A5202 was based on HR estimate, whereas, in the A5257, the primary efficacy analysis is now based on pairwise comparisons of Kaplan-Meier estimates for the week 96
(not from the entire failure time distribution) and equivalence will be accepted if the CI is entirely within AE10%. Thus, the criteria defined in the A5257 study would have led to equivalence if they had been applied to the A5202 study. Such differences between effect measures need to be highlighted and more widely understood because they potentially explain differences in the results observed between trials. Recent trials in the preexposure prophylaxis area even used the number needed to harm as effect measure. Beyond the debate on scale, we think that further discussion on primary endpoints, time to follow-up, and noninferiority limits are needed. Table 1 . Summary of the analyses in the A5202 study [5] and alternative analyses.
Abacavir-Lamivudine Tenofovir DF-Emtricitabine
Noninferiority margin EFV ATV/r EFV ATV/r (n ¼ 465) (n ¼ 463) (n ¼ 464) (n ¼ 465)
Original analysis: Time to virologic failure 96 week Events/persons at risk (K-M estimate), n/n (%)M
